Investors & Media
DevaCell is a preclinical-stage biopharmaceutical company focused on developing next-generation synthetic vector-based immunotherapies based on the ONCoat™ vector platform technology.
DevaCell is a preclinical-stage biopharmaceutical company focused on developing next-generation synthetic vector-based immunotherapies based on the ONCoat™ synthetic vector platform technology. We are advancing a pipeline of product candidates that can be systemically delivery, with repeat administration possible, targeting a wide range of indications with significant unmet medical need. Our lead therapeutic program, DEVA-OV1, is a synthetic vector-based oncolytic virus therapy that is designed to selectively target and kill tumor cells, while also delivering immunomodulatory transgenes that synergistically activate and enhance the innate and adaptive immune system.
Our personal and profession mission and commitment is to positively impact patient care, which inspires and motivates each and every one of us every single day to do more and do more faster, in order to move down the path to improved patient care.
PUBLICATIONS & PRESENTATIONS
BIO Investor Conference 2020
Slide Deck and One-Page Summary, October 2020
Ultrasound Detection of Regional Oxidative Stress in Deep Tissues Using Novel Enzyme Loaded Nanoparticles
Emilia S Olson, Inanc Ortac, Christopher Malone, Sadik Esener, Robert Mattrey
Advanced healthcare materials 2017 Mar;6(5), DOI: 10.1002/adhm.201601163
Dual-Porosity Hollow Nanoparticles for the Immunoprotection and Delivery of Nonhuman Enzymes
Inanc Ortac, Dmitri Simberg, Ya-san Yeh, Jian Yang, Bradley Messmer, William C. Trogler, Roger Y. Tsien, and Sadik Esener
Nano Letters 2014 14 (6), 3023-3032DOI: 10.1021/nl404360k